Lupeng Pharmaceutical
Shanghai, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
A CNS-focused biotech developing novel small molecules for neurodegenerative and psychiatric diseases.
Neuroscience
Technology Platform
A CNS-focused drug design platform that optimizes small molecules for blood-brain barrier penetration and employs predictive neuropharmacology models.
Opportunities
Large unmet medical need and potential for breakthrough therapy designation if clinical data is positive in challenging neurodegenerative diseases.
Risk Factors
Immense clinical development risk inherent to CNS trials, including difficulties in measuring efficacy and high placebo responses.
Competitive Landscape
Competes in the high-failure-risk CNS sector against global pharma giants, where demonstrating clear mechanistic differentiation is paramount.